piflufolastat F 18

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Lantheus Medical Imaging

Conditions

Clear Cell Renal Cell CarcinomaProstatic Neoplasm

Phase 2

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active, not recruitingNCT05849298

Novartis PharmaceuticalsProstatic Neoplasm

Start: 2024-01-03End: 2026-12-23Updated: 2026-03-03

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

WithdrawnNCT07084909

Lantheus Medical ImagingClear Cell Renal Cell Carcinoma

Start: 2025-11-30End: 2027-09-30Updated: 2025-12-10

Related Papers

Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients: a tumor marker prognostic study

International Journal of Surgery2025-03-263 citations